Trial Profile
Safety and Efficacy of Maraviroc-Based Graft-Versus-Host-Disease Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Donor Transplantation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Ciclosporin; Ciclosporin; Methotrexate; Tacrolimus
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 20 Jun 2016 New trial record